Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02049437 · ClinicalTrials.gov registry record · Phase 1
AIDS 347: IL-6 Blockade in Treated HIV Infection
A Phase 1 study, sponsored by Case Western Reserve University.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT02049437 is a Phase 1 study that has completed, run by Case Western Reserve University. The registered enrollment target is 34 participants.
The verdict
NCT02049437, a Phase 1 study, has completed, sponsored by Case Western Reserve University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The study is a phase I/II, double-blind, placebo-controlled, randomized cross-over clinical trial of tocilizumab (TCZ) or placebo in HIV-infected subjects receiving antiretroviral therapy with suppressed viral replication and CD4+ T cell count ≥350 and ≤1,000 cells/mm3)
Interventions
- DRUG Placebo
- DRUG tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-09-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02049437
The ClinicalTrials.gov registry entry for NCT02049437 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Western Reserve University, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02049437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02049437 about?
NCT02049437 is a clinical study titled "AIDS 347: IL-6 Blockade in Treated HIV Infection". The study is a phase I/II, double-blind, placebo-controlled, randomized cross-over clinical trial of tocilizumab (TCZ) or placebo in HIV-infected subjects receiving antiretroviral therapy with suppressed viral replication and CD4+ T cell count ≥350 and ≤1,000 cells/mm3)
What is the current status of trial NCT02049437?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2014-08. Estimated completion is 2017-09-11.
What interventions are being tested in trial NCT02049437?
The interventions under investigation include: Placebo (DRUG), tocilizumab (DRUG).
Who is sponsoring clinical trial NCT02049437?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.